For example, 47Sc, 67Cu or 212Pb offer better-suited half-lives than 177Lu and higher linear energy transfer than 90Y. Nevertheless, all anti-FAP radioligand therapies might also benefit from a synergistic combination with non-radioactive cancer therapeutics. This evidence concerns the gene FAP and cancer.